Therapeutic Indications

Ambroxol is indicated for:

Mucolytic therapy

Irrespective of gender only Children (1 year - 12 years old)

Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 7.5-15 mg 3 3 times daily

Treatment 2: Intravenous - 30 mg/kg body weight per day, divided into four single doses

Mucolytic therapy

Irrespective of gender only Adolescents (12 years - 18 years old) , Adults (18 - 65 years old)

Ambroxol is indicated for mucolytic therapy of productive cough associated with acute or chronic bronchopulmonary diseases.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravenous - 30 mg/kg body weight per day, divided into four single doses

Treatment 2: Oral - 30 mg 3 times daily

Contraindications

Active ingredient Ambroxol is contraindicated in the following cases:

Antitussives or with drugs that have an atropic effect

No gender/age discrimination

Ambroxol should not be given concomitantly with antitussives or with drugs that have an atropic effect.

Breast-feeding

No gender/age discrimination

Ambroxol crosses into the breast milk in animals. As there is no adequate experience in humans to date, ambroxol should only be used in lactation after careful benefit/risk assessment.

Pregnancy

No gender/age discrimination

There are no sufficient data for the use of ambroxol in pregnant women. This particularly concerns the period up to the 28th week of pregnancy. Ambroxol has shown no teratogenic effects in animal-experiment studies. Ambroxol should only be used in pregnancy after careful benefit/risk evaluation, particularly during the first trimester.